CASPOFUNGIN ACETATE | A200833 | JIANGSU HENGRUI PHARMACEUTICALS CO LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2010-05-06 | Terminated 2011-06-29 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.
Hengrui Pharma's caspofungin acetate NDA 200833 supplement 002 changed product type from RX (prescription) to DISCN (discontinued).
Old: RX
New: DISCN
Hengrui Pharma's caspofungin acetate (NDA 200833, supplement 002) lost reference-standard status.
Old: Yes
New: No
Hengrui Pharma's caspofungin acetate (Cancidas, NDA 200833) transitioned from prescription (RX) to discontinued (DISCN) status in the FDA Orange Book.
Old: RX
New: DISCN
Hengrui Pharma's caspofungin acetate (NDA 200833, supplement 002) therapeutic equivalence rating changed from AP to a different code.
Old: AP
Hengrui Pharma's CASPOFUNGIN ACETATE (NDA 200833) was removed from the Reference Standards list in the FDA Orange Book.
Old: Yes
New: No
Hengrui Pharma's caspofungin acetate (NDA 200833) therapeutic equivalence code changed from AP to a new designation, affecting generic substitutability assessment.
Old: AP